Banca de DEFESA: VANESSA MODESTO CÂNDIDO

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : VANESSA MODESTO CÂNDIDO
DATE: 28/03/2024
TIME: 14:00
LOCAL: Sala Virtual Remota https://bit.ly/Def_MCs_VanessaCandido_PGBIOEXP
TITLE:

.

KEY WORDS:

HDV; recombinant rHDVAg; ELISA; Immunodiagnosis

 

PAGES: 82
BIG AREA: Ciências Biológicas
AREA: Biologia Geral
SUMMARY:

The hepatitis delta virus (HDV) is highly pathogenic and is linked to the progression of serious liver diseases such as cirrhosis and cancer. HDV requires the presence of hepatitis B virus (HBV) for its replication and spread. An estimated 12 to 72 million people are infected worldwide with HDV. Despite high endemic indicators, infections caused by HDV represent a condition neglected by health services. The diagnosis of HDV has limitations due to the availability of inputs applicable to the detection and determination of viral infection. Aiming to produce relevant biotechnological resources for the purpose of detecting HDV infection, recombinant antigenic targets were developed from sequences of the delta antigen (HDVAg) of HDV genotypes I and III. The characterization of recombinant HDVAg (rHDVAg) was carried out and different variables were analyzed with a view to evaluating the application of this target for the indirect detection of HDV infections. To this end, serological assays were conducted to detect the presence of anti-HDVAg antibodies, using ELISA and a panel containing 170 serological samples. Of these, 66 sera were previously characterized by qRT-PCR, of which 46 were identified as seropositive for HDV and 20 as seronegative. Of these, 66 sera were previously characterized by qRT-PCR, of which 46 were identified as seropositive for HDV and 20 as seronegative. Likewise, to investigate possible cross-reactions, 104 samples previously characterized in relation to different viral infectious agents were used. Preliminary results from serological assays using rHDVAg-I and rHDVAg-III revealed a sensitivity of 53.66% and specificity of 90.0%, and a sensitivity of 95.7% and specificity of 90.0%, respectively. It was possible to demonstrate the effectiveness of rHDVAg-III in terms of its ability to specifically recognize infections caused by HDV. The partial data obtained in the enzymatic assays demonstrate that the product developed in this study has potential for diagnosing HDV. The phase I proof of concept demonstrated the ability to apply rHDVAg, for the purpose of developing diagnostic prototypes, which can comprise immunoenzymatic and chemiluminescent assays and constitute a rapid test device for detecting viral infection. Perspectively, it will be necessary to increase the number of samples tested from both endemic and non-endemic areas to complete the analysis comprehensively and advance to phase II of the study. It is important to highlight that the development of different diagnostic strategies with inputs of high sensitivity and specificity for the detection and/or screening of the rHDVAg antigenic target can assist in the prognosis and, with attention to preventing the evolution of the infection and reducing general costs related to complications. due to chronicity and will also allow attention to the patient in order to limit liver worsening caused by the HDV virus.

COMMITTEE MEMBERS:
Externo à Instituição - DANIEL ARCHIMEDES DA MATTA
Externo à Instituição - RITA DE CÁSSIA PONTELLO RAMPAZZO - FIOCRUZ
Presidente - ***.335.462-** - SORAYA DOS SANTOS PEREIRA - UNIR